News

Obesity Linked to Worse Outcomes in Common Breast Cancer Subtype

Publish date: December 10, 2010

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. Sparano and Dr. Garber declared they have no financial conflicts of interest.

Pages

Recommended Reading

Toxicity of Vandetanib Is Expected Focus for FDA Advisory Committee
MDedge Internal Medicine
TNF Inhibitors Appear to Reduce Diabetes Risk in RA
MDedge Internal Medicine
Overweight, Obesity Both Linked to Higher Mortality
MDedge Internal Medicine
Healthy People Launches 2020 Goals
MDedge Internal Medicine
Panel Supports Vandetanib for Medullary Thyroid Cancer
MDedge Internal Medicine
FDA Panel Supports Lowering BMI Criterion for Obesity Surgery
MDedge Internal Medicine
FDA, Orexigen Discussing CV Risk Study for Weight-Loss Drug Contrave
MDedge Internal Medicine
FDA Panel Supports Combination for Weight Loss
MDedge Internal Medicine
Even One Cigarette Is Harmful, Surgeon General's Report Finds
MDedge Internal Medicine
EMA Investigating Reports of Increased Mortality From Growth Hormones
MDedge Internal Medicine